CD274 and non-small cell lung carcinoma: Our study compared both PD-L1 and BiomeOne® test performance in a subcohort of NSCLC patients, showing that BiomeOne® can potentially outperform the PD-L1 expression test when identifying Rs. When used alone, PD-L1 is a rather weak biomarker [29], but a combination of biomarkers could potentially improve the detection of Rs and NRs.